// App-Quantinova.ai

435 : Post-hoc analysis of long-term outcomes in patients with CR, PR, or SD to pembrolizumab (pembro) or platinum-based chemotherapy (chemo) as 1L therapy for advanced urothelial carcinoma (UC) in KEYNOTE-361.

Researchers

Presenter

  • Yohann Loriot

Principal Investigators

  • Tibor Csoszi

  • Mustafa Ozguroglu

  • Nobuaki Matsubara

  • Lajos Geczi

  • Susanna Y. Cheng

  • Yves Fradet

  • Stephane Oudard

  • Christof Vulsteke

  • Rafael Morales-Barrera

  • Aude Flechon

  • Seyda Gunduz

  • Alejo Rodriguez-Vida

  • Ronac Mamtani

  • Evan Y. Yu

  • Chih-Chin Liu

  • Kentaro Imai

  • Blanca Homet Moreno

  • Thomas Powles

Medical Centers

  • Gustave Roussy, Universite Paris-Saclay, Villejuif, France

  • University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

  • Hetenyi G Korhaz, Onkologiai Kozpont, Szolnok, Hungary

  • Istanbul University, Cerrahpasa School of Medicine, Istanbul, Turkey

  • National Cancer Center, EPOC, Chiba, Japan

  • National Institute of Oncology, Budapest, Hungary

  • Sunnybrook Odette Cancer Centre, Toronto, ON, Canada

  • CHU de Quebec - Universite Laval, Quebec City, QC, Canada

  • Hopital European Georges Pompidou, Paris, France

  • Center for Oncological Research (CORE), University of Antwerp, Integrated Cancer Center Ghent, Ghent, Belgium

  • Vall d'Hebron Institute of Oncology, Barcelona, Spain

  • Centre Leon Berard, Lyon, France

  • Akdeniz University, Antalya, Turkey

  • Medical Oncology Department, Hospital del Mar Research Institute, Barcelona, Spain

  • Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

  • Division of Medical Genetics, Department of Medicine, University of Washington, Seattle, WA

  • Merck & Co., Inc., Kenilworth, NJ

  • Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

Locations

  • France

  • United States

  • Hungary

  • Turkey

  • Japan

  • Canada

  • Belgium

  • Spain

  • United Kingdom

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Advanced Urothelial Carcinoma

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • NCT02853305

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved